Kuceki G, Wambier CG, et al
Clinical Trial Results for Danuglipron Pfizer conducted Phase 2 clinical trials of danuglipron, which provided preliminary evidence of weight loss efficacy but also revealed significant tolerability challenges that ultimately halted the obesity development programme
Insulin secretion is enhanced only when blood glucose is elevated (glucose-dependent mechanism), substantially reducing hypoglycaemia risk compared to sulphonylureas
GLP-1s are powerful medications, and many users experience side effects including nausea, constipation, stomach pain, and reflux that can result in a drastically reduced food intake and rapid weight loss
Novo Nordisk's key formulation patent (US 9,714,283, filed 2013) covers the phosphate-buffered solution used in Ozempic and Wegovy, with specific pH ranges and phenol concentrations